What is the dose of lurasidone (Latuda)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

  1. 2 Depressive Episodes Associated with Bipolar I Disorder Adults The recommended starting dose of lurasidone hydrochloride tablets is 20 mg given once daily as monotherapy or as adjunctive therapy with lithium or valproate. Lurasidone hydrochloride tablets has been shown to be effective in a dose range of 20 mg per day to 120 mg per day as monotherapy or as adjunctive therapy with lithium or valproate The maximum recommended dose, as monotherapy or as adjunctive therapy with lithium or valproate, is 120 mg per day.
  • The recommended dose of lurasidone (Latuda) is:
    • Starting dose: 20 mg per day
    • Effective dose range: 20 mg per day to 120 mg per day
    • Maximum recommended dose: 120 mg per day 1

From the Research

Dose of Lurasidone (Latuda)

  • The recommended dose of lurasidone is 40-160 mg/day, administered once-daily with food 2, 3.
  • The recommended starting dose is 40 mg/day, and initial dose titration is not required 2, 4.
  • For bipolar depression, the dose range is 20-120 mg/day 3.
  • Lurasidone should be taken with food, as absorption is halved on an empty stomach 5.

Administration and Pharmacokinetics

  • Lurasidone is administered once daily, and its pharmacokinetic profile requires administration with food 3.
  • Peak plasma concentrations are reached in 1-3 hours, with a mean elimination half-life of 18 hours 3.
  • Lurasidone is approximately 99% bound to serum plasma proteins, and is principally metabolized by cytochrome P450 (CYP) 3A4 3.

Special Considerations

  • Lurasidone has a favorable metabolic profile, with minimal weight gain and no clinically-meaningful alterations in glucose, lipids, or the electrocardiogram corrected QT (ECG QTc) interval 2, 6.
  • Common adverse events include somnolence, akathisia, nausea, and parkinsonism 2, 4, 5, 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.